Freeline Granted ILAP Designation in UK by MHRA for FLT201

Freeline Therapeutics today announced that FLT201 has been awarded the Innovation Passport for the treatment of Gaucher disease type 1 under the Innovative Licensing and Access Pathway (ILAP) process by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA).

The Innovation Passport is the first step in the ILAP process, which in collaboration with MHRA and partner agencies, aims to accelerate time to market and facilitate patient access to medicines in the UK for life-threatening or seriously debilitating conditions, or conditions for which there is a significant patient or public health need.

Read the full story here.